Prayer as a Possible Adjuvant Treatment for Breast Cancer
1 other identifier
interventional
15
1 country
1
Brief Summary
The goal of this study is to help determine the biochemical mechanisms underlying previously demonstrated health benefits of prayer, and to track humoral changes in various prayer activities.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2006
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2006
CompletedFirst Submitted
Initial submission to the registry
August 20, 2007
CompletedFirst Posted
Study publicly available on registry
August 22, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2012
CompletedJanuary 24, 2012
January 1, 2012
5.8 years
August 20, 2007
January 23, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
A. Evaluate the effect of prayer on humoral (including biochemical/physiological inflammatory/immune) parameters approximately every three months at the subjects routine oncology visit.
2 years
B. Monitor changes in cancer- related biomarkers, and evaluate these changes in relation to the participants' prayer activities as recorded since the previous oncology visit.
2 years
C. Evaluate the effect of prayer on blood pressure, quality of life, health and dietary habits in relation to prayer activities, using validated questionnaires.
2 years
Study Arms (2)
1
EXPERIMENTALscripted prayer group (intervention group)
2
NO INTERVENTIONno prayer intervention group (non-intervention group)
Interventions
Eligibility Criteria
You may qualify if:
- Primary histological diagnosis of Stage I-IV breast cancer.
- Initial diagnosis of breast cancer within 5 year of study enrollment.
- Not currently receiving chemotherapy or radiation therapy. Hormone therapy is allowed.
- Life expectancy of at least 12 months.
- ECOG performance status of 0, 1, or 2.
- Willing to sign informed consent indicating that they are aware of the investigational nature of the study and the randomized study design.
- Willing to comply with monthly follow-up phone calls.
- Willing to complete questionnaires at regular oncology clinic visits.
- Able to read write \& understand English.
You may not qualify if:
- Concurrent treatment with chemotherapy or radiation therapy
- Less than 3 months since last dose of chemotherapy or radiation therapy.
- Breast cancer diagnosis more than 5 years prior to study enrollment
- Less than 21 or greater than to 80 years old.
- Life threatening or severe concurrent non-malignant conditions.
- Uncontrolled diabetes mellitus.
- Severe heart disease.
- Severe liver disease. Severe lung disease.
- History of smoking within 5 years of study enrollment.
- Psychological or psychiatric disorder that would interfere with study compliance.
- History of missed appointments or poor medical compliance.
- Inability to understand instructions on how to complete a questionnaire.
- No access to a phone.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Southwestern Regional Medical Centerlead
- Gateway for Cancer Researchcollaborator
Study Sites (1)
Cancer Treatment Centers of America at Southwestern Regional medical Center
Tulsa, Oklahoma, 74133, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stephen Ray, MD
Cancer Treatment Centers of America
- PRINCIPAL INVESTIGATOR
Petra Ketterl, MD
Cancer Treatment Centers of America at Southwestern Regional Medical Center
- PRINCIPAL INVESTIGATOR
Percy McCray, Rev.
Cancer Treatment Centers of America
- PRINCIPAL INVESTIGATOR
Michael Langham, Rev.
Cancer Treatment Centers of America at Southwestern Regional Medical Center
- PRINCIPAL INVESTIGATOR
Daniel Nixon, MD
Cancer Control Center of Charleston
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 20, 2007
First Posted
August 22, 2007
Study Start
March 1, 2006
Primary Completion
January 1, 2012
Study Completion
January 1, 2012
Last Updated
January 24, 2012
Record last verified: 2012-01